Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT03539055

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03539055
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03539055. Allocation not applicable; no masking; primary purpose prevention. Start 2018-09-01 (actual); primary completion 2023-12-31 (actual). Results posted on 2025-06-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
Acronym
DEA-LAA
Condition
Device Related Thrombus
Condition
Left Atrial Appendage Thrombosis
Condition
Watchman LAA Closure Device
Intervention (Drug)
Dabigatran Etexilate Oral Capsule
Lead sponsor
Vanderbilt University Medical Center (class: other)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct03539055
Content hash
bda88d59df2ade29649db2dadbe9b6e00cc0838d4f45bfeb56d37d882433b230